Antiarrhythmic effects of vernakalant in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with short QT syndrome type 1

(1) Background: Short QT syndrome (SQTS) may result in sudden cardiac death. So far, no drugs, except quinidine, have been demonstrated to be effective in some patients with SQTS type 1 (SQTS1). This study was designed to examine the potential effectiveness of vernakalant for treating SQTS1 patients...

Full description

Bibliographic Details

Main Authors:	Xu, Qiang (Author) , Huang, Xuemei (Author) , Meng, Zenghui (Author) , Li, Yingrui (Author) , Zhong, Rujia (Author) , Li, Xin (Author) , Cyganek, Lukas (Author) , El-Battrawy, Ibrahim (Author) , Akın, Ibrahim (Author) , Zhou, Xiao-Bo (Author) , Lan, Huan (Author)
Format:	Article (Journal)
Language:	English
Published:	9 April 2022
In:	Journal of cardiovascular development and disease Year: 2022, Volume: 9, Issue: 4, Pages: 1-14
ISSN:	2308-3425
DOI:	10.3390/jcdd9040112
Online Access:	Verlag, kostenfrei, Volltext: https://doi.org/10.3390/jcdd9040112 Verlag, kostenfrei, Volltext: https://www.mdpi.com/2308-3425/9/4/112
Author Notes:	Qiang Xu, Xuemei Huang, Zenghui Meng, Yingrui Li, Rujia Zhong, Xin Li, Lukas Cyganek, Ibrahim El-Battrawy, Ibrahim Akin, Xiaobo Zhou and Huan Lan